CRISPR Gene-Editing Therapy Achieves Near-Total Cure for Sickle Cell Disease

A groundbreaking gene-editing therapy has shown remarkable success in treating severe sickle cell disease (SCD). The RUBY Trial, using a one-time cellular treatment, achieved what researchers describe as a 'functional cure' for nearly all participants. This approach eliminates the need for donor compatibility and avoids the risks of traditional bone marrow transplants.

Sickle cell disease is caused by a mutation in the beta-globin gene, leading to misshapen red blood cells that damage organs and trigger painful crises. For years, bone marrow transplants offered the only potential cure, but they required matched donors and carried high risks of rejection or graft-versus-host disease.

The RUBY Trial tested **renizgamglogene autogedtemcel (reni-cel)**, a CRISPR-Cas12a-based therapy that edits a patient's own stem cells. After extracting stem cells and administering chemotherapy, doctors reinfused the edited cells. This method bypassed donor compatibility issues entirely. Twenty-eight patients with severe SCD took part, including four treated at Cleveland Clinic Children's. Within a month, their blood cell production recovered fully. By six months, total hemoglobin levels averaged **13.8 g/dL**, a significant improvement. Fetal hemoglobin—known to counteract sickle cell effects—rose to **48.1%** and remained stable. The results were striking: **27 of 28 participants** experienced complete resolution of painful sickle cell crises. As of April 2026, reni-cel remains in a single ongoing trial—the **Phase 1/2/3 REVCORD study** (NCT15482390), sponsored by Renaissance Gene Therapy. No additional trials are currently planned.

This gene-editing therapy marks a major advance in SCD treatment, offering a lasting solution without the limitations of donor-dependent transplants. The trial's success suggests a potential shift in how severe sickle cell disease could be managed in the future.